NHLBI-supported research is contributing to the evidence base that will one day be used to deliver precision medicine in clinical settings. To help achieve this goal, the NHLBI has launched an initiative in precision medicine aimed at the heart, lung, blood and sleep (HLBS) disorders that are central to its mission.
- Trans-Omics for Precision Medicine (TOPMed) is an NHLBI-wide initiative to generate scientific resources that will enhance our understanding of the fundamental biological processes underlying HLBS disorders. The TOPMed program will integrate
-omics (e.g., genomic, proteomic, metabolomic) and phenotypic data in an effort to improve the prediction, prevention, diagnosis, and treatment of these disorders.
- The NHLBI TOPMed program is designed to complement the activities of the National Institutes of Health (NIH) Precision Medicine Initiative Cohort Program and the President’s Precision Medicine Initiative. The NIH Precision Medicine Initiative Cohort Program will focus on cancer in the near term, while also developing of a national research cohort of one million or more U.S. participants to help study a range of health issues and diseases in the longer term.